)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
BioInvent International (BINV) investor relations material
BioInvent International Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Portfolio reprioritized to focus on BI-1808 and BI-1206, both in Phase II trials for liquid and solid tumors, with early-stage programs paused.
BI-1808 shows 100% disease control and 45% objective response in CTCL; BI-1206 initiated pivotal Phase 2a in first-line NSCLC and uveal melanoma.
Regulatory milestones include FDA Fast Track and Orphan Drug Designations for BI-1808 in T-cell lymphomas.
Board change: Vincent Osipo/Ossipow stepped down after nearly 10 years.
Accelerated clinical progress has led to earlier-than-expected data readouts.
Financial highlights
Q3 2025 net sales: SEK 3.3 million, down from SEK 12.8 million in Q3 2024; Jan–Sep 2025 net sales: SEK 223.5 million, up from SEK 23.3 million, mainly from a $20 million royalty rights deal.
Q3 2025 operating costs: SEK 137 million; Jan–Sep 2025: SEK 446 million.
Q3 2025 loss after tax: SEK -129.2 million; Jan–Sep 2025: SEK -207.1 million, improved from SEK -312.5 million.
Liquid funds and investments at end of Sep 2025: SEK 690.5 million; financing secured into Q1 2027.
Cash flow from operating activities Jan–Sep 2025: SEK -157.2 million, improved from SEK -282.2 million.
Outlook and guidance
Multiple data updates for BI-1808 and BI-1206 expected in 2025, including Phase II-A monotherapy and combination data.
First data from BI-1206 first-line solid tumor study expected in H2 2026.
Potential for pivotal studies in 2026 for BI-1808 monotherapy in T cell lymphoma and BI-1206 in NHL.
Focus on partnering opportunities as mature data emerges in 2026.
Sufficient funding to reach upcoming value inflection points.
Impact of portfolio focus on cash burn?
BI-1206's potential in first-line NSCLC?
Value contribution from outlicensed assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioInvent International earnings date
Q4 202527 Feb, 2026
Next BioInvent International earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage